Garadacimab in Hereditary Angioedema: Modeling Suggests Sustained Improvements in Attack-Free Probability and Quality of Life Over 5 Years.
- DOI
- 10.1111/cts.70737
- Published
- 2026 Oct
- Container
- Clinical and translational science
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1111/cts.70737,
title = {Garadacimab in Hereditary Angioedema: Modeling Suggests Sustained Improvements in Attack-Free Probability and Quality of Life Over 5 Years.},
author = {Li PH and Hsu FI and Aygören-Pürsün E and Lumry WR and Raasch J and Pragst I and Li Y and Nenci C and Campioni M and Magerl M},
year = {2026},
journal = {Clinical and translational science},
doi = {10.1111/cts.70737},
url = {https://doi.org/10.1111/cts.70737}
}RIS
TY - JOUR TI - Garadacimab in Hereditary Angioedema: Modeling Suggests Sustained Improvements in Attack-Free Probability and Quality of Life Over 5 Years. AU - Li PH AU - Hsu FI AU - Aygören-Pürsün E AU - Lumry WR AU - Raasch J AU - Pragst I AU - Li Y AU - Nenci C AU - Campioni M AU - Magerl M PY - 2026 JO - Clinical and translational science DO - 10.1111/cts.70737 UR - https://doi.org/10.1111/cts.70737 ER -
APA
PH, L., FI, H., E, A., WR, L., J, R., I, P., Y, L., C, N., M, C., & M, M. (2026). Garadacimab in Hereditary Angioedema: Modeling Suggests Sustained Improvements in Attack-Free Probability and Quality of Life Over 5 Years.. Clinical and translational science. https://doi.org/10.1111/cts.70737
Source records
- pubmed · retrieved 2026-11-10T14:30:24.993Z